David R. Spigel

Jul 3, 2024 | targetedonc.com | David R. Spigel

David Spigel, MD, chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, explains some of the unmet needs for patients with limited-stage small cell lung cancer (SCLC) and how they led to the initiation of the ADRIATIC trial (NCT03703297).

Jun 7, 2024 | onclive.com | David R. Spigel

CommentaryVideoJune 7, 2024Author(s):David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer. David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discusses findings from the first planned interim analysis of the phase 3 ADRIATIC trial (NCT03703297) in patients with limited-stage small cell lung cancer (LS-SCLC).

Apr 22, 2024 | ascopubs.org | David R. Spigel |Alejandro Navarro |James Yang

1 SCLC is characterized by a rapid doubling time and early metastases,2 and most patients present with extensive-stage or metastatic disease at diagnosis.3,4 The aggressive nature of SCLC means that affected patients face a poorer prognosis than those with any other type of lung cancer.

Mar 1, 2024 | jitc.bmj.com | Heinz-Josef Lenz |Aparna R. Parikh |David R. Spigel |Allen L. Cohn

DiscussionPhase 2 results from the CheckMate 9X8 trial did not demonstrate a statistically significant improvement in median PFS with nivolumab plus SOC versus SOC in the first-line treatment of patients with mCRC. The PFS curves overlapped before separating at approximately 12 months; nivolumab plus SOC showed numerically higher PFS rates after 12 months compared with SOC. PFS subgroup analyses showed a numerical trend favoring nivolumab plus SOC across multiple subgroups (HR<1).